Lung-focussed MRI technology developer Polarean Imaging said in an update on Thursday that it has received its first de novo order for a new Xenoview polariser.
A drug with a novel mechanism of action reduces tics and does not cause weight gain or tardive dyskinesia ― side effects that are associated with current medications for the disorder.